<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Cancer</journal-id><journal-id journal-id-type="iso-abbrev">JMIR Cancer</journal-id><journal-id journal-id-type="pmc-domain-id">3180</journal-id><journal-id journal-id-type="pmc-domain">jmircan</journal-id><journal-id journal-id-type="publisher-id">cancer</journal-id><journal-title-group><journal-title>JMIR Cancer</journal-title></journal-title-group><issn pub-type="epub">2369-1999</issn><publisher><publisher-name>JMIR Publications Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431160</article-id><article-id pub-id-type="pmcid-ver">PMC12431160.1</article-id><article-id pub-id-type="pmcaid">12431160</article-id><article-id pub-id-type="pmcaiid">12431160</article-id><article-id pub-id-type="pmid">40939065</article-id><article-id pub-id-type="doi">10.2196/69057</article-id><article-id pub-id-type="publisher-id">69057</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="primary-section"><subject>Cancer Prognosis Models and Machine Learning</subject></subj-group><subj-group subj-group-type="secondary-section"><subject>Clinical Information and Decision Making</subject></subj-group><subj-group subj-group-type="secondary-section"><subject>Machine Learning</subject></subj-group><subj-group subj-group-type="secondary-section"><subject>Innovations and Technology in Cancer Care</subject></subj-group><subj-group subj-group-type="secondary-section"><subject>Clinical Cancer Research</subject></subj-group><subj-group subj-group-type="secondary-section"><subject>Cancer Survivorship</subject></subj-group><subj-group subj-group-type="secondary-section"><subject>Innovations in Cancer Diagnostic and Decision Support</subject></subj-group><subj-group subj-group-type="secondary-section"><subject>Imaging Informatics</subject></subj-group><subj-group subj-group-type="secondary-section"><subject>Obstetrics, Gynecology, and Reproductive Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Machine Learning for Preoperative Assessment and Postoperative Prediction in Cervical Cancer: Multicenter Retrospective Model Integrating MRI and Clinicopathological Data</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-4467-6773</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="S">Shuqi</given-names></name><degrees>BMed</degrees><xref rid="aff1" ref-type="aff">1</xref><xref rid="equal-contrib1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1203-5705</contrib-id><name name-style="western"><surname>Guo</surname><given-names initials="C">Chenyan</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">1</xref><xref rid="equal-contrib1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-3031-6623</contrib-id><name name-style="western"><surname>Fang</surname><given-names initials="Y">Yufei</given-names></name><degrees>BSc</degrees><xref rid="aff2" ref-type="aff">2</xref><xref rid="equal-contrib1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2063-2684</contrib-id><name name-style="western"><surname>Qiu</surname><given-names initials="J">Junjun</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">1</xref><xref rid="equal-contrib1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3782-1411</contrib-id><name name-style="western"><surname>Zhang</surname><given-names initials="H">He</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-5122-1478</contrib-id><name name-style="western"><surname>Ling</surname><given-names initials="L">Lei</given-names></name><degrees>BSc</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9233-4363</contrib-id><name name-style="western"><surname>Xu</surname><given-names initials="J">Jie</given-names></name><degrees>DHM</degrees><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9868-0136</contrib-id><name name-style="western"><surname>Peng</surname><given-names initials="X">Xinwei</given-names></name><degrees>MMed</degrees><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-8800-8202</contrib-id><name name-style="western"><surname>Jiang</surname><given-names initials="C">Chuchu</given-names></name><degrees>MSc</degrees><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6509-8219</contrib-id><name name-style="western"><surname>Wang</surname><given-names initials="J">Jue</given-names></name><degrees>MPH</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4546-5229</contrib-id><name name-style="western"><surname>Hua</surname><given-names initials="K">Keqin</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp"/></contrib><aff id="aff1"><label>1</label><institution content-type="department">Shanghai Key Lab of Female Reproductive Endocrine Related Diseases, Shanghai Key Lab of Reproduction and Development</institution>, <institution>Obstetrics and Gynecology Hospital of Fudan University</institution>, <addr-line>218 Shenyang Road</addr-line>, <addr-line content-type="city">Shanghai</addr-line>, <addr-line>200433</addr-line>, <country>China</country>, <phone>86 021 33189900</phone></aff><aff id="aff2"><label>2</label><institution content-type="department">Department of Pharmaceutical Sciences</institution>, <institution>Academy of Pharmacy, Xi&#8217;an Jiaotong Liverpool University</institution>, <addr-line content-type="city">Suzhou</addr-line>, <country>China</country></aff><aff id="aff3"><label>3</label><institution>Shanghai Artificial Intelligence Laboratory</institution>, <addr-line content-type="city">Shanghai</addr-line>, <country>China</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Cahill</surname><given-names initials="N">Naomi</given-names></name></contrib></contrib-group><author-notes><fn fn-type="equal" id="equal-contrib1"><label>*</label><p>these authors contributed equally</p></fn><corresp id="cor1">Keqin Hua, MD, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases, Shanghai Key Lab of Reproduction and Development, Obstetrics and Gynecology Hospital of Fudan University, 218 Shenyang Road, Shanghai, 200433, China, <phone>86 021 33189900</phone>; <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="huakeqin@fudan.edu.cn">huakeqin@fudan.edu.cn</email></corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>12</day><month>9</month><year>2025</year></pub-date><volume>11</volume><issue-id pub-id-type="pmc-issue-id">479784</issue-id><elocation-id>e69057</elocation-id><history><date date-type="received"><day>22</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>28</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Shuqi Li, Chenyan Guo, Yufei Fang, Junjun Qiu, He Zhang, Lei Ling, Jie Xu, Xinwei Peng, Chuchu Jiang, Jue Wang, Keqin Hua. Originally published in JMIR Cancer (https://cancer.jmir.org)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cancer, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://cancer.jmir.org/">https://cancer.jmir.org/</ext-link>, as well as this copyright and license information must be included.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cancer-v11-e69057.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="cancer-v11-e69057.pdf"/><abstract><title>Abstract</title><sec><title>Background</title><p>Machine learning (ML) has been increasingly applied to cervical cancer (CC) research. However, few studies have combined both clinical parameters and imaging data. At the same time, there remains an urgent need for more robust and accurate preoperative assessment of parametrial invasion and lymph node metastasis, as well as postoperative prognosis prediction.</p></sec><sec><title>Objective</title><p>The objective of this study is to develop an integrated ML model combining clinicopathological variables and magnetic resonance image features for (1) preoperative parametrial invasion and lymph node metastasis detection and (2) postoperative recurrence and survival prediction.</p></sec><sec><title>Methods</title><p>Retrospective data from 250 patients with CC (2014&#8208;2022; 2 tertiary hospitals) were analyzed. Variables were assessed for their predictive value regarding parametrial invasion, lymph node metastasis, survival, and recurrence using 7 ML models: K-nearest neighbor (KNN), support vector machine, decision tree, random forest (RF), balanced RF, weighted DT, and weighted KNN. Performance was assessed via 5-fold cross-validation using accuracy, sensitivity, specificity, precision, F1-score, and area under the receiver operating characteristic curve (AUC). The optimal models were deployed in an artificial intelligence&#8211;assisted contouring and prognosis prediction system.</p></sec><sec><title>Results</title><p>Among 250 women, there were 11 deaths and 24 recurrences. (1) For preoperative evaluation, the integrated model using balanced RF achieved optimal performance (sensitivity 0.81, specificity 0.85) for parametrial invasion, while weighted KNN achieved the best performance for lymph node metastasis (sensitivity 0.98, AUC 0.72). (2) For postoperative prognosis, weighted KNN also demonstrated high accuracy for recurrence (accuracy 0.94, AUC 0.86) and mortality (accuracy 0.97, AUC 0.77), with relatively balanced sensitivity of 0.80 and 0.33, respectively. (3) An artificial intelligence&#8211;assisted contouring and prognosis prediction system was developed to support preoperative evaluation and postoperative prognosis prediction.</p></sec><sec><title>Conclusions</title><p>The integration of clinical data and magnetic resonance images provides enhanced diagnostic capability to preoperatively detect parametrial invasion and lymph node metastasis detection and prognostic capability to predict recurrence and mortality for CC, facilitating personalized, precise treatment strategies.</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><title>Keywords</title><kwd>cervical cancer</kwd><kwd>integrated prediction model</kwd><kwd>machine learning</kwd><kwd>multimodal integration</kwd><kwd>diagnostic model</kwd><kwd>prognosis prediction model</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>As the fourth leading cause of cancer-related death in women, cervical cancer (CC) accounted for approximately 661,000 new cases and 341,800 deaths worldwide in 2022 [<xref rid="R1" ref-type="bibr">1</xref>]. Despite advances in clinical management, up to 30% of patients continue to succumb to the disease, resulting in a disproportionately high global burden [<xref rid="R2" ref-type="bibr">2</xref>]. However, current methods for preoperative evaluation and postoperative prognosis prediction in patients with CC remain insufficiently comprehensive. Preoperative assessment relies heavily on pelvic magnetic resonance (MR) imaging to identify primary lesions [<xref rid="R3" ref-type="bibr">3</xref>], whereas the recognition rates for parametrial invasion and lymphatic metastases remain inconsistent [<xref rid="R4" ref-type="bibr">4</xref>]. Furthermore, for postoperative prognosis prediction, the International Federation of Gynecology and Obstetrics (FIGO) staging system is currently accepted as the clinical standard. However, it fails to fully account for patient heterogeneity, including factors such as age, general health status, and tumor markers. Therefore, a personalized prognostic estimation system is urgently needed. To address this, researchers have explored various statistical methods&#8212;such as logistic regression and Cox proportional hazards models&#8212;to estimate survival and recurrence outcomes on an individual basis [<xref rid="R5" ref-type="bibr">5</xref><xref rid="R6" ref-type="bibr">6</xref>]. Nonetheless, traditional statistical models are often limited in their ability to handle large, complex datasets and make accurate predictions in dynamic clinical environments. To this end, a more accurate and personalized prediction model&#8212;incorporating both preoperative and postoperative evaluation&#8212;is urgently needed to optimize treatment decisions and follow-up strategies for patients with CC.</p><p>In recent years, machine learning (ML)&#8212;which involves the development of dynamic algorithms capable of making data-driven decisions&#8212;has emerged as a novel method for processing medical data and has been widely applied to various diseases [<xref rid="R7" ref-type="bibr">7</xref>]. In the field of CC, our previous multicenter study developed a web-based calculator to predict prognosis in 5112 patients with CC using various ML models, which demonstrated better predictive accuracy than traditional statistical models [<xref rid="R8" ref-type="bibr">8</xref>]. However, similar to other studies [<xref rid="R9" ref-type="bibr">9-11</xref>], only clinicopathological information was included in the development of this ML model. Notably, with technological advancements, medical imaging can now reveal information imperceptible to the naked eye&#8212;even for experienced clinicians. Consequently, an increasing number of studies have used deep learning (DL) algorithms on MR images for the diagnosis [<xref rid="R12" ref-type="bibr">12</xref><xref rid="R13" ref-type="bibr">13</xref>] and classification [<xref rid="R14" ref-type="bibr">14</xref>] of CC. However, most existing studies have focused on lesion identification [<xref rid="R15" ref-type="bibr">15</xref><xref rid="R16" ref-type="bibr">16</xref>] and radiotherapy response prediction [<xref rid="R17" ref-type="bibr">17</xref><xref rid="R18" ref-type="bibr">18</xref>]. Currently, there is a lack of ML models that integrate both clinical and imaging data to predict prognosis in patients with CC. Therefore, we aimed to develop an integrated ML model that uses both clinical and imaging data to enhance preoperative evaluation and postoperative prognosis prediction.</p><p>Specifically, the model is designed to (1) accurately evaluate parametrial involvement and lymph node metastasis on pelvic MR images prior to surgery to better inform surgical planning, and (2) predict individualized postoperative recurrence and survival outcomes to support precise, personalized adjuvant treatment and follow-up strategies.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>Ethical Considerations</title><p>This retrospective multicenter cohort study received ethical approval from the Institutional Review Board of the Obstetrics and Gynecology Hospital of Fudan University (Shanghai, China; approval no. 2019&#8208;87) and registered with the Chinese Clinical Trial Registry (ChiCTR1900028702). Oral informed consent was obtained from all participants via telephone follow-up in accordance with institutional ethical standards. All personally identifiable information was permanently removed prior to analysis. Data were coded using unique identifiers and stored securely on encrypted, password-protected servers with role-based access controls to ensure confidentiality. No compensation was provided to participants.</p></sec><sec id="s2-2"><title>Patients</title><p>A total of 1076 patients with CC who underwent surgical resection between January 2014 and December 2022 were identified from 2 tertiary hospitals in China: the Obstetrics and Gynecology Hospital affiliated with Fudan University and Shanghai First Maternity and Infant Hospital. The inclusion criteria were as follows: (1) pathologically confirmed FIGO stage IA1 with positive lymph-vascular space invasion (LVSI) to stage IIB CC; (2) radical hysterectomy performed according to National Comprehensive Cancer Network (NCCN) guidelines appropriate to the disease stage at the time [<xref rid="R19" ref-type="bibr">19-21</xref>]; (3) availability of high-quality preoperative pelvic contrast-enhanced MR images, including the coronal T2-weighted imaging (T2WI) fat-suppressed sequence; and (4) at least 3 years of follow-up data. The exclusion criteria were as follows: (1) receipt of chemotherapy or radiotherapy before surgery (n=23); (2) incomplete medical records (n=61); (3) absence of preoperative MR imaging (MRI) or MRI performed at another institution (n=536); (4) unsatisfactory MR image quality (n=98); and (5) loss to follow-up (n=108). The final study population comprised 250 patients (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><title> Flow diagram illustrating the selection process for the study population and the sequential stages of machine learning model development. FIGO: International Federation of Gynecology and Obstetrics; LVSI: lymph-vascular space invasion; T2WI: T2-weighted imaging; MR: magnetic resonance; KNN: K-nearest neighbor; SVM: support vector machine; DT: decision tree; RF: random forest; RT: regression tree; RFS: recurrence-free survival; OS: overall survival.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cancer-v11-e69057-g001.jpg"/></fig></sec><sec id="s2-3"><title>Clinical Information</title><p>For eligible patients, demographic data, laboratory test results, treatment details, and tumor characteristics were collected from medical records. All records were reviewed concurrently by 3 experts and independently verified for accuracy by 2 additional reviewers. Following diagnosis, demographic variables&#8212;including age and comorbidity (hypertension or diabetes)&#8212;as well as laboratory data, including squamous cell carcinoma antigen levels and human papillomavirus (HPV) infection status, were recorded. The history of the loop electrosurgical excision procedure was also noted.</p><p>All surgical procedures during the study period were performed by faculty members with completed fellowship training in gynecologic oncology. Surgical data included surgical approach, operative time, estimated blood loss, and use of blood transfusion. Tumor characteristics included FIGO stage, tumor size, histologic type, depth of stromal invasion (DSI), LVSI, surgical margin status, parametrial involvement, lymph node metastasis, keratinization, degree of differentiation, and expression of P53, P16, and Ki-67. According to the NCCN guidelines [<xref rid="R3" ref-type="bibr">3</xref>], all patients received adjuvant therapy if they met one of the following criteria: (1) presence of any high-risk factor, including positive surgical margins, parametrial involvement, or lymph node metastasis; or (2) fulfillment of any Sedlis criteria [<xref rid="R22" ref-type="bibr">22</xref>] for intermediate-risk factors, including tumor size, LVSI, and DSI.</p><p>Patients were followed according to the 2022 NCCN guidelines [<xref rid="R3" ref-type="bibr">3</xref>] after discharge and completion of initial treatment. HPV testing, liquid-based cytology, tumor marker evaluation, and ultrasonography were conducted every 3 months for the first 2 years, every 6 months for the next 2 years, and annually thereafter. Chest computed tomography (CT), contrast-enhanced upper abdominal CT, and pelvic MRI were performed annually. Telephone follow-ups were also conducted, and patients with symptoms or abnormal findings suggestive of recurrence were advised to undergo the aforementioned tests. In cases of suspected organ or lymph node metastasis, needle aspiration biopsy was performed when clinically indicated.</p></sec><sec id="s2-4"><title>Region of Interest Delineation on MR Images</title><p>Coronal preoperative T2WI fat-suppressed pelvic contrast-enhanced MR images were collected for all 250 patients. This included both the original MR sequence source images and lesion segmentation images annotated by radiologists. The MR source images were first normalized before further processing. To standardize the 2 types of MR source image resolutions (256&#215;256 pixels and 320&#215;320 pixels), images of 320&#215;320 pixels were center-cropped to 256&#215;256 pixels. Meanwhile, the pixel intensity values, which originally ranged from 0 to over 1000, were rescaled to the range [0, 1]. After obtaining standardized MR source images, 2 experienced radiologists performed lesion annotations. The region of interest for CC was manually delineated on T2WI images using ITK-SNAP (version 3.8.0). Each radiologist delineated half of the cases and independently reviewed the other half. In cases of disagreement, the final decision was reached through discussion or by consulting a third radiologist. During the segmentation process, the radiologists were blinded to the patients&#8217; clinical information.</p><p>After obtaining standardized MR source images, 2 experienced radiologists performed lesion annotations. The region of interest for CC was manually delineated on T2WI images using ITK-SNAP (version 3.8.0). Each radiologist delineated half of the cases and independently reviewed the other half. In cases of disagreement, the final decision was reached through discussion or by consulting a third radiologist. During the segmentation process, the radiologists were blinded to the patients&#8217; clinical information.</p><p>Subsequently, cervical lesion identification was modeled using the radiologist-annotated MR images. An optimized algorithm based on the 3D U-Net architecture [<xref rid="R23" ref-type="bibr">23</xref>], embedded with a squeeze-and-excitation layer [<xref rid="R24" ref-type="bibr">24</xref>], was adopted to segment the lesion pixels. Following multiple preprocessing steps (see Supplementary Materials in <xref rid="SAP1" ref-type="supplementary-material">Multimedia Appendix 1</xref>), the input data (C&#215;W&#215;H&#215;D) were compressed and normalized using the Sigmoid activation function [<xref rid="R25" ref-type="bibr">25</xref>], then reshaped to their original dimensions. The grayscale output was segmented by computing the probability of each pixel being classified as a positive sample through the Sigmoid function. To address the issue of sample imbalance&#8212;where MR image sequences contained significantly more frames with lesion markers than without&#8212;an improved Focal Loss function [<xref rid="R26" ref-type="bibr">26</xref>] was implemented. A weighting factor (&#945;) was applied to balance positive and negative samples, while a power function was used to reduce the loss contribution of easy samples. The optimal parameters used in this study were <italic toggle="yes">&#945;</italic>=.25 and <italic toggle="yes">&#947;</italic>=2.</p></sec><sec id="s2-5"><title>Outcome</title><p>Parametrial invasion and lymphatic metastasis were 2 key pathological indicators derived from the surgical specimens of cervical carcinoma. Parametrial invasion refers to the infiltration of neoplastic cells beyond the cervix into the surrounding connective tissue (parametrium), while lymphatic metastasis denotes the spread of malignant cells to regional lymph nodes.</p><p>For survival outcomes, recurrence-free survival (RFS) was defined as the interval from the initial CC diagnosis to either the first documented recurrence or the last follow-up. Overall survival (OS) was defined as the interval from diagnosis to CC&#8211;related death or the last follow-up. Regarding recurrence classification, local recurrence was defined as the pathologically confirmed first reappearance of cancer in the cervix or vagina following complete treatment, confined to the pelvic region. Distant recurrence was defined as the first pathologically confirmed relapse beyond the pelvis, including peritoneal dissemination or metastasis to distant organs.</p></sec><sec id="s2-6"><title>Dataset Processing</title><p>After selecting MR source images that corresponded to lesion-annotated segmentation files, the filtered original images (256&#215;256 pixels) were flattened into 65,536-dimensional vectors. The clinical dataset consisted of 22 variables (Table S1 in <xref rid="SAP1" ref-type="supplementary-material">Multimedia Appendix 1</xref>), including both continuous and categorical features. Continuous variables were normalized using min-max scaling, rescaling each feature into the [0, 1] range using the following formula:</p><disp-formula id="eqnwl1"><mml:math id="M1" alttext="X_{norm}=\frac{X-X_{min}}{X_{max}-X_{min}}" overflow="scroll"><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>X</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula><p>where <inline-formula><mml:math id="M2" alttext="X_{min}" overflow="scroll"><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M3" alttext="X_{max}" overflow="scroll"><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cancer-v11-e69057-i001.jpg"/> represent the minimum and maximum observed values of that feature. For example, for a variable ranging from 2 to 10, a value of 5 would be transformed as: (5&#8211;2)/(10&#8211;2)=0.375. Categorical variables were encoded using one-hot encoding, which converts nominal variables into orthogonal binary vectors. For a categorical feature with 3 classes (1, 2, 3), the transformation was as follows: Class 1 &#8594; [1, 0, 0]; Class 2 &#8594; [0, 1, 0]; and Class 3 &#8594; [0, 0, 1].</p><p>After preprocessing, categorical and continuous variables were concatenated into 5-dimensional (preoperative) and 57-dimensional (postoperative) clinical feature vectors. These clinical vectors were then fused with the 65,536-dimensional image vectors, resulting in integrated feature vectors of 65,593 dimensions.</p></sec><sec id="s2-7"><title>Establishment of Integrated Models</title><p>Two integrated models were developed: (1) The preoperative recognition model integrated preoperative clinical parameters (age, comorbidity, HPV status, squamous cell antigen carcinoma level, and loop electrosurgical excision procedure history) and MR images to generate binary classifications for parametrial invasion and lymph node metastasis; and (2) the postoperative prognostic model combined 21 postoperative clinical parameters (Table S1 in <xref rid="SAP1" ref-type="supplementary-material">Multimedia Appendix 1</xref>) and MR images to predict recurrence, mortality, and individualized RFS or OS times.</p><p>A total of 7 ML algorithms were used for model construction. These included classical ML algorithms such as K-nearest neighbor (KNN), support vector machine (SVM), decision tree (DT), and random forest (RF), as well as their imbalanced-data variants&#8212;weighted KNN, balanced RF, and weighted DT. Weighted KNN adjusted sample weights inversely proportional to class frequency. Specifically, minority class samples (in this study, positive cases) were assigned higher weights in distance calculations, forcing the algorithm to prioritize minority class neighborhoods during prediction. Balanced RF used under-sampling by randomly removing majority class samples (negative cases) in each bootstrap iteration to create balanced subsets for training individual trees. Weighted DT modified the splitting criterion by incorporating a class-weighted penalty: a weight of misclassifying a positive sample was set to amplify the cost of false negatives during node splitting. Besides, to mitigate the influence of class imbalance during model development, negative samples were down-sampled to achieve a 1:1 ratio with positive cases during training.</p></sec><sec id="s2-8"><title>Validation, Evaluation, and Implementation</title><p>The study process consisted of 4 main stages: patient data input, data preprocessing, model development, and model evaluation (<xref rid="F1" ref-type="fig">Figure 1</xref>). Stratified random sampling was used to divide the complete dataset from the 2 hospitals into training and test sets at a ratio of 8:2. Model training was conducted using the training set, while final validation was performed on the test set. To minimize overfitting and reduce bias, 5-fold cross-validation was used on the training set for hyperparameter tuning.</p><p>Model performance for classification tasks was evaluated using sensitivity, specificity, accuracy, precision, F1-score, weighted accuracy, and area under the receiver operating characteristic curve (AUC). The mean absolute error (MAE) and concordance index (C-index) were used to assess the accuracy of individual-specific RFS and OS time predictions.</p><p>To facilitate clinical application and enhance accessibility for physicians, a web-based predictive diagnostic support tool was developed using Python, enabling DICOM upload and automated prediction.</p></sec><sec id="s2-9"><title>Statistical Analysis</title><p>Continuous variables were reported as means with standard deviations (SDs) for normally distributed data and as medians with interquartile ranges (IQRs) for non-normally distributed data, while categorical variables were summarized as counts and percentages. No significant interactions were observed among variables based on correlation matrix analysis. Concordance of continuous variables was assessed using intraclass correlation coefficients to evaluate consistency between pathology and imaging reports. Categorical variables were analyzed using the <italic toggle="yes">&#967;<sup>2</sup></italic> test and the Kappa coefficient.</p><p>All statistical analyses were performed using R statistical software (version 4.1.1; R Foundation for Statistical Computing) and Python programming software (version 3.10.4; Python Software Foundation). All tests were 2-sided, and a <italic toggle="yes">P</italic> value of less than .05 was considered statistically significant unless otherwise stated.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3-1"><title>Baseline Characteristics of 250 Patients with Early-Stage CC</title><p>A total of 250 patients with FIGO stage IA1 (LVSI+) to IIB CC who underwent radical hysterectomy between 2014 and 2022 were included in the study population (<xref rid="T1" ref-type="table">Table 1</xref>). The median age was 48.8 years. Most patients were at stage I (n=182, 72.8%) and had a squamous histologic type (n=200, 80%). More than half of the patients (n=191, 76.4%) received adjuvant therapy. In total, 24 women (9.6%) experienced recurrence, and 11 (4.4%) died during the follow-up period. Among the recurrence cases, 9 (37.5%) were local recurrences and 15 (62.5%) were distant. Among the distant recurrences, 4 (16.7%) occurred in the thoracic region, 5 (20.8%) in the abdominal region, and 6 (25%) in bone. The median RFS was 33.8 (IQR 24.9&#8208;42.4) months, and the median OS was 34.6 (IQR 26.0&#8208;42.8) months. The 1-year RFS and OS rates were 94.4% and 99.2%, respectively, while the 3-year RFS and OS rates were 90.1% and 95.4%, respectively (Figure S1 in <xref rid="SAP1" ref-type="supplementary-material">Multimedia Appendix 1</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><title> Baseline characteristics of patients with stage IA1 (LVSI+)<xref rid="T1_FN2" ref-type="table-fn"><sup>a</sup></xref> to IIB CC<xref rid="T1_FN18" ref-type="table-fn"><sup>b</sup></xref>. Data are reported as number of patients and percentage of total in parentheses, unless otherwise noted.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1">Characteristics</th><th valign="bottom" rowspan="1" colspan="1">Overall (n=250)</th><th valign="bottom" rowspan="1" colspan="1">Train (n=200)</th><th valign="bottom" rowspan="1" colspan="1">Test (n=50)</th><th valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td colspan="5" align="left" valign="top" rowspan="1">Clinical variables</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Age at diagnosis (years), mean (SD<xref rid="T1_FN17" ref-type="table-fn"><sup>c</sup></xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">48.8 (9.6)</td><td align="left" valign="top" rowspan="1" colspan="1">48.3 (9.7)</td><td align="left" valign="top" rowspan="1" colspan="1">50.9 (9.1)</td><td align="left" valign="top" rowspan="1" colspan="1">.09</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;FIGO<xref rid="T1_FN4" ref-type="table-fn"><sup>d</sup></xref> stage, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.40</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;IA1</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;IA2</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;IB1</td><td align="left" valign="top" rowspan="1" colspan="1">148 (59.2)</td><td align="left" valign="top" rowspan="1" colspan="1">123 (61.5)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (50.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;IB2</td><td align="left" valign="top" rowspan="1" colspan="1">32 (12.8)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (13.0)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (12.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;IIA1</td><td align="left" valign="top" rowspan="1" colspan="1">52 (20.8)</td><td align="left" valign="top" rowspan="1" colspan="1">37 (18.5)</td><td align="left" valign="top" rowspan="1" colspan="1">15 (30.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;IIA2</td><td align="left" valign="top" rowspan="1" colspan="1">14 (5.6)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (5.5)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (6.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;IIB</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;Comorbidity, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.73</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Yes</td><td align="left" valign="top" rowspan="1" colspan="1">41 (16.4)</td><td align="left" valign="top" rowspan="1" colspan="1">32 (16.0)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (18.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;No</td><td align="left" valign="top" rowspan="1" colspan="1">209 (83.6)</td><td align="left" valign="top" rowspan="1" colspan="1">168 (84.0)</td><td align="left" valign="top" rowspan="1" colspan="1">41 (82.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;HPV<xref rid="T1_FN5" ref-type="table-fn"><sup>e</sup></xref> infection, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.34</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Yes</td><td align="left" valign="top" rowspan="1" colspan="1">117 (46.8)</td><td align="left" valign="top" rowspan="1" colspan="1">91 (45.5)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (52.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;HPV 16/18</td><td align="left" valign="top" rowspan="1" colspan="1">74 (29.6)</td><td align="left" valign="top" rowspan="1" colspan="1">60 (30.0)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (28.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Other HPV type</td><td align="left" valign="top" rowspan="1" colspan="1">43 (17.2)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (15.5)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (24.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;No</td><td align="left" valign="top" rowspan="1" colspan="1">6 (2.4)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (3.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">127 (50.8)</td><td align="left" valign="top" rowspan="1" colspan="1">103 (51.5)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (48.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;SCCA<xref rid="T1_FN6" ref-type="table-fn"><sup>f</sup></xref> (ng/mL), median (IQR)<xref rid="T1_FN7" ref-type="table-fn"><sup>g</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">2.1 (1.0&#8208;4.9)</td><td align="left" valign="top" rowspan="1" colspan="1">2.1 (1.0&#8208;5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (0.8&#8208;4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">.93</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;Post-surgery adjuvant therapy, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.94</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Yes</td><td align="left" valign="top" rowspan="1" colspan="1">191 (76.4)</td><td align="left" valign="top" rowspan="1" colspan="1">153 (76.5)</td><td align="left" valign="top" rowspan="1" colspan="1">38 (76.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;No</td><td align="left" valign="top" rowspan="1" colspan="1">59 (23.6)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (23.5)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (24.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Surgery-related variables</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;Surgery approach, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;MH<xref rid="T1_FN8" ref-type="table-fn"><sup>h</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">246 (98.4)</td><td align="left" valign="top" rowspan="1" colspan="1">197 (98.5)</td><td align="left" valign="top" rowspan="1" colspan="1">49 (98.0)</td><td align="left" valign="top" rowspan="1" colspan="1">.56</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;LH<xref rid="T1_FN9" ref-type="table-fn"><sup>i</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">221 (88.4)</td><td align="left" valign="top" rowspan="1" colspan="1">175 (87.5)</td><td align="left" valign="top" rowspan="1" colspan="1">46 (92.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Robotic</td><td align="left" valign="top" rowspan="1" colspan="1">25 (10.0)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (11.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (6.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;OH<xref rid="T1_FN10" ref-type="table-fn"><sup>j</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">4 (1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Operative time (min), median (IQR)</td><td align="left" valign="top" rowspan="1" colspan="1">180.0 (159.0&#8208;225.0)</td><td align="left" valign="top" rowspan="1" colspan="1">180.0 (157.0&#8208;222.5)</td><td align="left" valign="top" rowspan="1" colspan="1">180.0 (160.0&#8208;230.0)</td><td align="left" valign="top" rowspan="1" colspan="1">.80</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Blood loss (mL), median (IQR)</td><td align="left" valign="top" rowspan="1" colspan="1">200.0 (100.0&#8208;300.0)</td><td align="left" valign="top" rowspan="1" colspan="1">200.0 (100.0&#8208;200.0)</td><td align="left" valign="top" rowspan="1" colspan="1">200.0 (100.0&#8208;300.0)</td><td align="left" valign="top" rowspan="1" colspan="1">.12</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Transfusion, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">.26</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Yes</td><td align="left" valign="top" rowspan="1" colspan="1">5 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;No</td><td align="left" valign="top" rowspan="1" colspan="1">245 (98.0)</td><td align="left" valign="top" rowspan="1" colspan="1">197 (98.5)</td><td align="left" valign="top" rowspan="1" colspan="1">48 (96.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Pathologic variables</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;Tumor size (cm) , n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;[0, 0.5)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (3.2)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (3.0)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;[0.5, 1)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;[1, 1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (5.2)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (3.0)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (14.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;[1.5, 2)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (5.2)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (6.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;[2, 2.5)</td><td align="left" valign="top" rowspan="1" colspan="1">33 (13.2)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (13.0)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (14.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;[2.5, 3)</td><td align="left" valign="top" rowspan="1" colspan="1">29 (11.6)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (13.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (6.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;[3, 3.5)</td><td align="left" valign="top" rowspan="1" colspan="1">38 (15.2)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (15.5)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (14.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;[3.5, 4)</td><td align="left" valign="top" rowspan="1" colspan="1">39 (15.6)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (15.5)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (16.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;[4, 4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">23 (9.2)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (10.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (6.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;[4.5, 5)</td><td align="left" valign="top" rowspan="1" colspan="1">23 (9.2)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (8.0)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (14.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;&#8805;5</td><td align="left" valign="top" rowspan="1" colspan="1">28 (11.2)</td><td align="left" valign="top" rowspan="1" colspan="1">23 (11.5)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (10.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;Histology, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;SCC<xref rid="T1_FN11" ref-type="table-fn"><sup>k</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">200 (80.0)</td><td align="left" valign="top" rowspan="1" colspan="1">161 (80.5)</td><td align="left" valign="top" rowspan="1" colspan="1">39 (78.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;AC<xref rid="T1_FN12" ref-type="table-fn"><sup>l</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">29 (11.6)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (12.5)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (8.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;AS<xref rid="T1_FN13" ref-type="table-fn"><sup>m</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">19 (7.6)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (6.0)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (14.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Rare type</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;DSI<xref rid="T1_FN14" ref-type="table-fn"><sup>n</sup></xref>, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.51</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Negative</td><td align="left" valign="top" rowspan="1" colspan="1">24 (9.6)</td><td align="left" valign="top" rowspan="1" colspan="1">21 (10.5)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (6.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Inner 1/3</td><td align="left" valign="top" rowspan="1" colspan="1">30 (12.0)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (13.0)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (8.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Middle 1/3</td><td align="left" valign="top" rowspan="1" colspan="1">28 (11.2)</td><td align="left" valign="top" rowspan="1" colspan="1">21 (10.5)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (14.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Outer 1/3</td><td align="left" valign="top" rowspan="1" colspan="1">168 (67.2)</td><td align="left" valign="top" rowspan="1" colspan="1">132 (66.0)</td><td align="left" valign="top" rowspan="1" colspan="1">36 (72.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;LVSI, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Yes</td><td align="left" valign="top" rowspan="1" colspan="1">145 (58.0)</td><td align="left" valign="top" rowspan="1" colspan="1">120 (60.0)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (50.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;No</td><td align="left" valign="top" rowspan="1" colspan="1">105 (42.0)</td><td align="left" valign="top" rowspan="1" colspan="1">80 (40.0)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (50.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;Surgical margin involvement, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.78</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Yes</td><td align="left" valign="top" rowspan="1" colspan="1">32 (12.8)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (12.5)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (14.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;No</td><td align="left" valign="top" rowspan="1" colspan="1">218 (87.2)</td><td align="left" valign="top" rowspan="1" colspan="1">175 (87.5)</td><td align="left" valign="top" rowspan="1" colspan="1">43 (86.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;Parametrial involvement, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.61</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Yes</td><td align="left" valign="top" rowspan="1" colspan="1">16 (6.4)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (6.0)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (8.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;No</td><td align="left" valign="top" rowspan="1" colspan="1">234 (93.6)</td><td align="left" valign="top" rowspan="1" colspan="1">188 (94.0)</td><td align="left" valign="top" rowspan="1" colspan="1">46 (92.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;Lymph node metastasis, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.35</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Yes</td><td align="left" valign="top" rowspan="1" colspan="1">64 (25.6)</td><td align="left" valign="top" rowspan="1" colspan="1">51 (25.5)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (26.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Pelvic lymph nodes</td><td align="left" valign="top" rowspan="1" colspan="1">54 (21.6)</td><td align="left" valign="top" rowspan="1" colspan="1">45 (22.5)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (18.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Common iliac lymph nodes</td><td align="left" valign="top" rowspan="1" colspan="1">6 (2.4)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Para-aortic lymph nodes</td><td align="left" valign="top" rowspan="1" colspan="1">4 (1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;No</td><td align="left" valign="top" rowspan="1" colspan="1">186 (74.4)</td><td align="left" valign="top" rowspan="1" colspan="1">149 (74.5)</td><td align="left" valign="top" rowspan="1" colspan="1">37 (74.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;Keratinization, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.96</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Yes</td><td align="left" valign="top" rowspan="1" colspan="1">87 (34.8)</td><td align="left" valign="top" rowspan="1" colspan="1">71 (35.5)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (32.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;No</td><td align="left" valign="top" rowspan="1" colspan="1">92 (36.8)</td><td align="left" valign="top" rowspan="1" colspan="1">73 (36.5)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (38.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Non-SCC</td><td align="left" valign="top" rowspan="1" colspan="1">50 (20.0)</td><td align="left" valign="top" rowspan="1" colspan="1">39 (19.5)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (22.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">21 (8.4)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (8.5)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (8.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;Differentiation, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.04</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Low</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Intermediate</td><td align="left" valign="top" rowspan="1" colspan="1">4 (1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;High</td><td align="left" valign="top" rowspan="1" colspan="1">2 (0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">243 (97.2)</td><td align="left" valign="top" rowspan="1" colspan="1">196 (98.0)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (94.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;P53, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.48</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;&#8211;</td><td align="left" valign="top" rowspan="1" colspan="1">73 (29.2)</td><td align="left" valign="top" rowspan="1" colspan="1">60 (30.0)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (26.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;+</td><td align="left" valign="top" rowspan="1" colspan="1">172 (68.8)</td><td align="left" valign="top" rowspan="1" colspan="1">137 (68.5)</td><td align="left" valign="top" rowspan="1" colspan="1">35 (70.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;++</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;+++</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;++++</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">5 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;P16, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.27</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Negative</td><td align="left" valign="top" rowspan="1" colspan="1">5 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Positive</td><td align="left" valign="top" rowspan="1" colspan="1">240 (96.0)</td><td align="left" valign="top" rowspan="1" colspan="1">194 (97.0)</td><td align="left" valign="top" rowspan="1" colspan="1">46 (92.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">5 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;Ki67, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.86</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;&#8212;</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;0%&#8208;20%</td><td align="left" valign="top" rowspan="1" colspan="1">16 (6.4)</td><td align="left" valign="top" rowspan="1" colspan="1">13 (6.5)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (6.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;20%&#8208;40%</td><td align="left" valign="top" rowspan="1" colspan="1">48 (19.2)</td><td align="left" valign="top" rowspan="1" colspan="1">37 (18.5)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (22.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;40%&#8208;60%</td><td align="left" valign="top" rowspan="1" colspan="1">77 (30.8)</td><td align="left" valign="top" rowspan="1" colspan="1">61 (30.5)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (32.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;60%&#8208;80%</td><td align="left" valign="top" rowspan="1" colspan="1">71 (28.4)</td><td align="left" valign="top" rowspan="1" colspan="1">60 (30.0)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (22.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;80%&#8208;100%</td><td align="left" valign="top" rowspan="1" colspan="1">32 (12.8)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (12.5)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (14.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">6 (2.4)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Survival outcomes</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;Recurrence, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.59</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Yes</td><td align="left" valign="top" rowspan="1" colspan="1">24 (9.6)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (9.0)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (12.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Local region</td><td align="left" valign="top" rowspan="1" colspan="1">9 (3.6)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (3.5)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Thoracic region</td><td align="left" valign="top" rowspan="1" colspan="1">4 (1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Abdominal region</td><td align="left" valign="top" rowspan="1" colspan="1">5 (2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Bone</td><td align="left" valign="top" rowspan="1" colspan="1">6 (2.4)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (3.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Other regions</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;No</td><td align="left" valign="top" rowspan="1" colspan="1">226 (90.4)</td><td align="left" valign="top" rowspan="1" colspan="1">182 (91.0)</td><td align="left" valign="top" rowspan="1" colspan="1">44 (88.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;RFS<xref rid="T1_FN15" ref-type="table-fn"><sup>o</sup></xref> (month), median (IQR)</td><td align="left" valign="top" rowspan="1" colspan="1">33.8 (24.9&#8208;42.4)</td><td align="left" valign="top" rowspan="1" colspan="1">33.2 (24.5&#8208;42.6)</td><td align="left" valign="top" rowspan="1" colspan="1">35.0 (26.8&#8208;41.4)</td><td align="left" valign="top" rowspan="1" colspan="1">.49</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">&#8195;Death, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">.54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;Yes</td><td align="left" valign="top" rowspan="1" colspan="1">11 (4.4)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (6.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;&#8195;No</td><td align="left" valign="top" rowspan="1" colspan="1">239 (95.6)</td><td align="left" valign="top" rowspan="1" colspan="1">192 (96.0)</td><td align="left" valign="top" rowspan="1" colspan="1">47 (94.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">OS<xref rid="T1_FN16" ref-type="table-fn"><sup>p</sup></xref> (month), median (IQR)</td><td align="left" valign="top" rowspan="1" colspan="1">34.6 (26.0&#8208;42.8)</td><td align="left" valign="top" rowspan="1" colspan="1">34.2 (25.3&#8208;43.0)</td><td align="left" valign="top" rowspan="1" colspan="1">35.0 (27.9&#8208;41.4)</td><td align="left" valign="top" rowspan="1" colspan="1">.47</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN2" fn-type="other"><label>a</label><p>LVSI: lymphovascular space invasion.</p></fn><fn id="T1_FN18" fn-type="other"><label>b</label><p>CC: cervical cancer.</p></fn><fn id="T1_FN17" fn-type="other"><label>c</label><p>SD: standard deviation.</p></fn><fn id="T1_FN4" fn-type="other"><label>d</label><p>FIGO: International Federation of Gynecology and Obstetrics.</p></fn><fn id="T1_FN5" fn-type="other"><label>e</label><p>HPV: human papillomavirus.</p></fn><fn id="T1_FN6" fn-type="other"><label>f</label><p>SCCA: squamous cell carcinoma antigen.</p></fn><fn id="T1_FN7" fn-type="other"><label>g</label><p>IQR: interquartile range.</p></fn><fn id="T1_FN8" fn-type="other"><label>h</label><p>MH: minimally invasive hysterectomy.</p></fn><fn id="T1_FN9" fn-type="other"><label>i</label><p>LH: laparoscopic hysterectomy.</p></fn><fn id="T1_FN10" fn-type="other"><label>j</label><p>OH: open hysterectomy.</p></fn><fn id="T1_FN11" fn-type="other"><label>k</label><p>SCC: squamous cell carcinoma.</p></fn><fn id="T1_FN12" fn-type="other"><label>l</label><p>AC: adenocarcinoma.</p></fn><fn id="T1_FN13" fn-type="other"><label>m</label><p>AS: adenosquamous carcinoma.</p></fn><fn id="T1_FN14" fn-type="other"><label>n</label><p>DSI: depth of stromal invasion.</p></fn><fn id="T1_FN15" fn-type="other"><label>o</label><p>RFS: recurrence-free survival.</p></fn><fn id="T1_FN16" fn-type="other"><label>p</label><p>OS: overall survival.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-2"><title>Preoperative Diagnostic Performance</title><p>Integrated models combining MR images with 5 clinical parameters demonstrated variable performance across 7 ML algorithms (<xref rid="T2" ref-type="table">Table 2</xref>).</p><p>For parametrial invasion diagnosis, classical ML models generally exhibited poor sensitivity (0.00&#8208;0.57). Specifically, RF and KNN failed to detect any positive cases (sensitivity=0.00), while SVM and DT showed low sensitivity (0.57 and 0.50) and specificity (0.56 and 0.59). On the contrary, imbalanced-data variants exhibited improved performance: (1) Balanced RF achieved balanced metrics (sensitivity=0.81, specificity=0.85, F1-score=0.64); (2) weighted KNN attained high sensitivity (0.98), while weighted DT prioritized specificity (0.93).</p><p>For lymph node metastasis detection, classical ML models showed limited sensitivity (0.31&#8208;0.66), with RF achieving high specificity (0.87) and SVM delivering the best traditional performance (sensitivity=0.66, specificity=0.52, F1-score=0.54). Imbalanced-data variants exhibited enhancements: (1) Weighted KNN demonstrated optimal overall performance (sensitivity=0.67, specificity +=0.61, F1-score=0.58); (2) balanced RF achieved high specificity (0.87) and precision (0.68); and (3) weighted DT showed marginal improvement over classical DT (sensitivity=0.38 vs 0.53, F1-score=0.42 vs 0.49).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2.</label><caption><title>The result of the preoperative diagnosis using various kinds of integrated ML<xref rid="T2_FN2" ref-type="table-fn"><sup>a</sup></xref> models for patients with stage IA1 (LVSI+)<xref rid="T2_FN3" ref-type="table-fn"><sup>b</sup></xref> to IIB CC<xref rid="T2_FN4" ref-type="table-fn"><sup>c</sup></xref>. All models were constructed using both MRI and clinical data.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1">Models</th><th valign="bottom" rowspan="1" colspan="1">Sensitivity</th><th valign="bottom" rowspan="1" colspan="1">Specificity</th><th valign="bottom" rowspan="1" colspan="1">Accuracy</th><th valign="bottom" rowspan="1" colspan="1">Precision</th><th valign="bottom" rowspan="1" colspan="1">F1-score</th></tr></thead><tbody><tr><td colspan="6" align="left" valign="top" rowspan="1">Parametrial invasions prediction</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Classical ML</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;KNN<xref rid="T2_FN5" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td><td align="left" valign="top" rowspan="1" colspan="1">0.83</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;SVM<xref rid="T2_FN6" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">0.56</td><td align="left" valign="top" rowspan="1" colspan="1">0.56</td><td align="left" valign="top" rowspan="1" colspan="1">0.21</td><td align="left" valign="top" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;DT<xref rid="T2_FN7" ref-type="table-fn"><sup>f</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="left" valign="top" rowspan="1" colspan="1">0.59</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">0.20</td><td align="left" valign="top" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;RF<xref rid="T2_FN8" ref-type="table-fn"><sup>g</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td><td align="left" valign="top" rowspan="1" colspan="1">0.83</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unbalanced ML</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Balanced RF</td><td align="left" valign="top" rowspan="1" colspan="1">0.81</td><td align="left" valign="top" rowspan="1" colspan="1">0.85</td><td align="left" valign="top" rowspan="1" colspan="1">0.85</td><td align="left" valign="top" rowspan="1" colspan="1">0.53</td><td align="left" valign="top" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Weighted KNN</td><td align="left" valign="top" rowspan="1" colspan="1">0.98</td><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.37</td><td align="left" valign="top" rowspan="1" colspan="1">0.21</td><td align="left" valign="top" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Weighted DT</td><td align="left" valign="top" rowspan="1" colspan="1">0.29</td><td align="left" valign="top" rowspan="1" colspan="1">0.93</td><td align="left" valign="top" rowspan="1" colspan="1">0.82</td><td align="left" valign="top" rowspan="1" colspan="1">0.46</td><td align="left" valign="top" rowspan="1" colspan="1">0.35</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1">Lymph node metastasis prediction</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Classical ML</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;KNN</td><td align="left" valign="top" rowspan="1" colspan="1">0.31</td><td align="left" valign="top" rowspan="1" colspan="1">0.77</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">0.46</td><td align="left" valign="top" rowspan="1" colspan="1">0.37</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;SVM</td><td align="left" valign="top" rowspan="1" colspan="1">0.66</td><td align="left" valign="top" rowspan="1" colspan="1">0.52</td><td align="left" valign="top" rowspan="1" colspan="1">0.57</td><td align="left" valign="top" rowspan="1" colspan="1">0.46</td><td align="left" valign="top" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;DT</td><td align="left" valign="top" rowspan="1" colspan="1">0.53</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">0.58</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.49</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;RF</td><td align="left" valign="top" rowspan="1" colspan="1">0.33</td><td align="left" valign="top" rowspan="1" colspan="1">0.87</td><td align="left" valign="top" rowspan="1" colspan="1">0.66</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unbalanced ML</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Balanced RF</td><td align="left" valign="top" rowspan="1" colspan="1">0.45</td><td align="left" valign="top" rowspan="1" colspan="1">0.87</td><td align="left" valign="top" rowspan="1" colspan="1">0.71</td><td align="left" valign="top" rowspan="1" colspan="1">0.68</td><td align="left" valign="top" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Weighted KNN</td><td align="left" valign="top" rowspan="1" colspan="1">0.67</td><td align="left" valign="top" rowspan="1" colspan="1">0.61</td><td align="left" valign="top" rowspan="1" colspan="1">0.63</td><td align="left" valign="top" rowspan="1" colspan="1">0.52</td><td align="left" valign="top" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Weighted DT</td><td align="left" valign="top" rowspan="1" colspan="1">0.38</td><td align="left" valign="top" rowspan="1" colspan="1">0.74</td><td align="left" valign="top" rowspan="1" colspan="1">0.60</td><td align="left" valign="top" rowspan="1" colspan="1">0.47</td><td align="left" valign="top" rowspan="1" colspan="1">0.42</td></tr></tbody></table><table-wrap-foot><fn id="T2_FN2" fn-type="other"><label>a</label><p>ML: machine learning.</p></fn><fn id="T2_FN3" fn-type="other"><label>b</label><p>LVSI: lymphovascular space invasion.</p></fn><fn id="T2_FN4" fn-type="other"><label>c</label><p>CC: cervical cancer.</p></fn><fn id="T2_FN5" fn-type="other"><label>d</label><p>KNN: K-nearest neighbors.</p></fn><fn id="T2_FN6" fn-type="other"><label>e</label><p>SVM: support vector machine.</p></fn><fn id="T2_FN7" fn-type="other"><label>f</label><p>DT: decision tree.</p></fn><fn id="T2_FN8" fn-type="other"><label>g</label><p>RF: random forest.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-3"><title>Postoperative Prediction Performance</title><p>For prognostic prediction (<xref rid="T3" ref-type="table">Table 3</xref>), all classical ML models (KNN, SVM, DT, and RF) failed to identify recurrence or mortality cases (sensitivity=0.00). Imbalanced data variants exhibited divergent outcomes: For recurrence prediction, (1) weighted KNN achieved clinically actionable performance (sensitivit=0.80, specificity=0.96, F1-score=0.73); (2) balanced RF detected recurrences effectively (sensitivity=0.80) but exhibited poor specificity (0.37); and (3) weighted DT failed to identify recurrence cases (sensitivity=0.00). For mortality prediction, (1) weighted KNN showed perfect specificity and precision (specificity=0.99, precision=0.99) but demonstrated low sensitivity (0.33); (2) balanced RF showed limited detection capability (sensitivity=0.33, F1-score=0.11); and (3) weighted DT failed to identify mortality cases (sensitivity=0.00). Among all models, weighted KNN yielded the highest AUC for recurrence (0.861) and mortality (0.765) (<xref rid="F2" ref-type="fig">Figure 2</xref>). Given the importance of sensitivity in guiding postoperative treatment and follow-up, weighted accuracy was introduced as an evaluation metric, and multiple weighting strategies were tested (Table S2 in <xref rid="SAP1" ref-type="supplementary-material">Multimedia Appendix 1</xref>). Results revealed that increasing the weight of sensitivity led to improved detection accuracy for potential recurrence and mortality cases.</p><p>For individualized survival time prediction (<xref rid="T4" ref-type="table">Table 4</xref>), weighted KNN achieved the best performance for recurrence with the lowest MAE (8.53 mo) and highest C-index (0.83), while regression tree (RT) achieved the best performance for mortality (MAE=4.36 mo; C-index=0.99).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3.</label><caption><title>The result of postoperative prognosis prediction using various kinds of integrated ML<xref rid="T3_FN4" ref-type="table-fn"><sup>a</sup></xref> models for patients with stage IA1 (LVSI+)<xref rid="T3_FN2" ref-type="table-fn"><sup>b</sup></xref> to IIB CC<xref rid="T3_FN3" ref-type="table-fn"><sup>c</sup></xref>. All models were constructed using both MRI and clinical data.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1">Models</th><th valign="bottom" rowspan="1" colspan="1">Sensitivity</th><th valign="bottom" rowspan="1" colspan="1">Specificity</th><th valign="bottom" rowspan="1" colspan="1">Accuracy</th><th valign="bottom" rowspan="1" colspan="1">Precision</th><th valign="bottom" rowspan="1" colspan="1">F1-score</th></tr></thead><tbody><tr><td colspan="6" align="left" valign="top" rowspan="1">Recurrence prediction</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Classical ML</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;KNN<xref rid="T3_FN5" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.89</td><td align="left" valign="top" rowspan="1" colspan="1">0.89</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;SVM<xref rid="T3_FN6" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.89</td><td align="left" valign="top" rowspan="1" colspan="1">0.89</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;DT<xref rid="T3_FN7" ref-type="table-fn"><sup>f</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.89</td><td align="left" valign="top" rowspan="1" colspan="1">0.87</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;RF<xref rid="T3_FN8" ref-type="table-fn"><sup>g</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.89</td><td align="left" valign="top" rowspan="1" colspan="1">0.89</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unbalanced ML</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Balanced RF</td><td align="left" valign="top" rowspan="1" colspan="1">0.80</td><td align="left" valign="top" rowspan="1" colspan="1">0.37</td><td align="left" valign="top" rowspan="1" colspan="1">0.41</td><td align="left" valign="top" rowspan="1" colspan="1">0.12</td><td align="left" valign="top" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Weighted KNN</td><td align="left" valign="top" rowspan="1" colspan="1">0.80</td><td align="left" valign="top" rowspan="1" colspan="1">0.96</td><td align="left" valign="top" rowspan="1" colspan="1">0.94</td><td align="left" valign="top" rowspan="1" colspan="1">0.67</td><td align="left" valign="top" rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Weighted DT</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.96</td><td align="left" valign="top" rowspan="1" colspan="1">0.86</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1">Mortality prediction</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Classical ML</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;KNN</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.92</td><td align="left" valign="top" rowspan="1" colspan="1">0.92</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;SVM</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.92</td><td align="left" valign="top" rowspan="1" colspan="1">0.92</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;DT</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.92</td><td align="left" valign="top" rowspan="1" colspan="1">0.92</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;RF</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.92</td><td align="left" valign="top" rowspan="1" colspan="1">0.92</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unbalanced ML</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Balanced RF</td><td align="left" valign="top" rowspan="1" colspan="1">0.33</td><td align="left" valign="top" rowspan="1" colspan="1">0.71</td><td align="left" valign="top" rowspan="1" colspan="1">0.69</td><td align="left" valign="top" rowspan="1" colspan="1">0.07</td><td align="left" valign="top" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Weighted KNN</td><td align="left" valign="top" rowspan="1" colspan="1">0.33</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td><td align="left" valign="top" rowspan="1" colspan="1">0.97</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td><td align="left" valign="top" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Weighted DT</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.96</td><td align="left" valign="top" rowspan="1" colspan="1">0.86</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="left" valign="top" rowspan="1" colspan="1">0.00</td></tr></tbody></table><table-wrap-foot><fn id="T3_FN4" fn-type="other"><label>a</label><p>ML: machine learning.</p></fn><fn id="T3_FN2" fn-type="other"><label>b</label><p>LVSI: lymphovascular space invasion.</p></fn><fn id="T3_FN3" fn-type="other"><label>c</label><p>CC: cervical cancer.</p></fn><fn id="T3_FN5" fn-type="other"><label>d</label><p>KNN: K-nearest neighbors.</p></fn><fn id="T3_FN6" fn-type="other"><label>e</label><p>SVM: support vector machine.</p></fn><fn id="T3_FN7" fn-type="other"><label>f</label><p>DT: decision tree.</p></fn><fn id="T3_FN8" fn-type="other"><label>g</label><p>RF: random forest.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F2" fig-type="figure" orientation="portrait"><label>Figure 2.</label><caption><title>Receiver operating characteristic curves for postoperative recurrence and mortality prediction in patients with International Federation of Gynecology and Obstetrics stage IA1 (lymph-vascular space invasion+) to IIB CC using various integrated weighted K-nearest neighbor (KNN) models. The x-axis represents 1-specificity, and the y-axis represents sensitivity. (A and B) Integrated models incorporating both clinical parameters and magnetic resonance imaging data were used to evaluate parametrial invasion (A) and lymph node metastasis (B). (C and D) Integrated models incorporating both clinical parameters and MRI data were used to predict postoperative recurrence (C) and mortality (D).</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cancer-v11-e69057-g002.jpg"/></fig><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4.</label><caption><title>The mean absolute error and C-index of postoperative RFS<xref rid="T4_FN2" ref-type="table-fn"><sup>a</sup></xref> and OS<xref rid="T4_FN3" ref-type="table-fn"><sup>b</sup></xref> prediction using integrated models using MR<xref rid="T4_FN4" ref-type="table-fn"><sup>c</sup></xref> and clinical parameters for patients with stage IA1 (LVSI +)<xref rid="T4_FN5" ref-type="table-fn"><sup>d</sup></xref> to IIB CC<xref rid="T4_FN6" ref-type="table-fn"><sup>e</sup></xref>. All models were constructed using both MR images and clinical data.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1">Models</th><th valign="bottom" rowspan="1" colspan="1">Mean absolute error (month)</th><th valign="bottom" rowspan="1" colspan="1">Concordance index</th></tr></thead><tbody><tr><td colspan="3" align="left" valign="top" rowspan="1">RFS prediction</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Weighted KNN<xref rid="T4_FN7" ref-type="table-fn"><sup>f</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">8.53</td><td align="left" valign="top" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;SVM<xref rid="T4_FN8" ref-type="table-fn"><sup>g</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">9.13</td><td align="left" valign="top" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;RF<xref rid="T4_FN9" ref-type="table-fn"><sup>h</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">8.83</td><td align="left" valign="top" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;RT<xref rid="T4_FN10" ref-type="table-fn"><sup>i</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">10.74</td><td align="left" valign="top" rowspan="1" colspan="1">0.17</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">OS prediction</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Weighted KNN</td><td align="left" valign="top" rowspan="1" colspan="1">4.69</td><td align="left" valign="top" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;SVM</td><td align="left" valign="top" rowspan="1" colspan="1">5.31</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;RF</td><td align="left" valign="top" rowspan="1" colspan="1">19.81</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;RT</td><td align="left" valign="top" rowspan="1" colspan="1">4.36</td><td align="left" valign="top" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn id="T4_FN2" fn-type="other"><label>a</label><p>RFS: recurrence-free survival.</p></fn><fn id="T4_FN3" fn-type="other"><label>b</label><p>OS: overall survival.</p></fn><fn id="T4_FN4" fn-type="other"><label>c</label><p>MR: magnetic resonance.</p></fn><fn id="T4_FN5" fn-type="other"><label>d</label><p>LVSI: lymphovascular space invasion.</p></fn><fn id="T4_FN6" fn-type="other"><label>e</label><p>CC: cervical cancer.</p></fn><fn id="T4_FN7" fn-type="other"><label>f</label><p>KNN: K-nearest neighbors.</p></fn><fn id="T4_FN8" fn-type="other"><label>g</label><p>SVM: support vector machine.</p></fn><fn id="T4_FN9" fn-type="other"><label>h</label><p>RF: random forest.</p></fn><fn id="T4_FN10" fn-type="other"><label>i</label><p>RT: regression tree.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-4"><title>AI-Assisted Contouring and Prognosis Prediction System</title><p>To enhance the clinical applicability of the prediction model and improve physicians&#8217; access, usability, and integration into practice, the optimal artificial intelligence (AI) prediction models were embedded into a web-based software platform designed to assist in preoperative evaluation and prognosis prediction on MR images (<xref rid="F3" ref-type="fig">Figure 3</xref>) [<xref rid="R27" ref-type="bibr">27</xref>]. By inputting key preoperative clinical parameters and uploading DICOM (DCM) files of preoperative MR images, the system can automatically identify possible lesions and generate predictions regarding the patient&#8217;s risk of parametrial invasion and lymphatic metastasis. Similarly, by entering relevant postoperative clinical, surgical, and pathological data along with uploading postoperative MR images, the system can estimate the patient&#8217;s risk of recurrence and mortality, as well as predict individualized durations of RFS and OS.</p><fig position="float" id="F3" fig-type="figure" orientation="portrait"><label>Figure 3.</label><caption><title>Screenshots of the web-based diagnostic software [<xref rid="R27" ref-type="bibr">27</xref>] developed to assist with preoperative evaluation of parametrial invasion and lymph node metastasis, and to predict postoperative recurrence and mortality, including individualized recurrence-free survival (RFS) and overall survival (OS) estimations. (A) By inputting the required clinical parameters and uploading MR images in DICOM format, users initiate analysis through the &#8220;submit&#8221; function. (B) Following submission, the software evaluates the possible lesion area and generates predictions for parametrial invasion and lymph node metastasis. If the &#8220;surgery status&#8221; is set to &#8220;postoperative,&#8221; probabilities of recurrence and mortality as well as specific RFS and OS estimations will be generated.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cancer-v11-e69057-g003.jpg"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><sec id="s4-1"><title>Principal Findings</title><p>This study developed integrated ML models combining clinicopathological characteristics with MRI data for preoperative assessment of parametrial invasion and lymph node metastasis, alongside postoperative prognosis prediction in early-stage CC. Our key findings demonstrate the following: (1) Integrated models improved diagnosing sensitivity of parametrial invasion and lymph node metastasis, enhancing preoperative staging accuracy to better guide surgical plan; (2) postoperative prognostic models achieved robust performance in individualized recurrence (AUC 0.861) and survival prediction (AUC 0.765), providing a novel tool for precise adjuvant treatment and individualized follow-up strategy; and (3) a clinically deployable AI platform operationalizes these models for clinical workflow integration, enabling automated risk stratification.</p></sec><sec id="s4-2"><title>Comparison to Prior Work</title><sec id="s4-2-1"><title>Preoperative Assessment</title><p>Our integrated models outperformed existing approaches. For parametrial invasion, balanced RF achieved substantially higher sensitivity (0.81) and F1-score (0.64) than a pathology-based clinical model (sensitivity 0.53, F1-score 0.54 calculated) [<xref rid="R9" ref-type="bibr">9</xref>], suggesting complete MRI provides more comprehensive prognostic information. While some studies reported better predictive performance for lymph node metastasis using axial T2WI + ADC sequences (sensitivity 0.87, specificity 0.70) [<xref rid="R15" ref-type="bibr">15</xref>], this discrepancy likely stems from our use of coronal T2WI versus their multi-planar/functional protocols. Crucially, our integrated models surpass radiologist assessments for both parametrial invasion (sensitivity 0.62&#8208;0.75, specificity 0.84&#8208;0.87) [<xref rid="R28" ref-type="bibr">28</xref><xref rid="R29" ref-type="bibr">29</xref>] and lymph node metastasis (sensitivity 0.54, AUC 0.65) [<xref rid="R30" ref-type="bibr">30</xref>], further validating the advantage of integrating clinical and imaging data in preoperative staging and surgical planning [<xref rid="R31" ref-type="bibr">31</xref>].</p></sec><sec id="s4-2-2"><title>Postoperative Prognosis</title><p>Weighted KNN&#8217;s strong performance (recurrence AUC 0.861; survival AUC 0.765) reflects its unique suitability for our clinical context. Unlike DL architectures requiring massive datasets to realize their potential, this non-parametric method leverages local neighborhood patterns while resisting overfitting, proving particularly effective for limited-sample scenarios where conventional DL advantages remain constrained [<xref rid="R32" ref-type="bibr">32</xref><xref rid="R33" ref-type="bibr">33</xref>]. Critically, this technical alignment serves a fundamental clinical imperative: prognostic prediction prioritizes minimizing missed recurrences (false negatives), where diagnostic harm substantially outweighs false positives, reflecting radiologists&#8217; conservative tendency to avoid overdiagnosis. To operationalize this priority, we implemented weighted accuracy metrics&#8212;demonstrating that elevating sensitivity weights enhances high-risk case detection (Table S2 in <xref rid="SAP1" ref-type="supplementary-material">Multimedia Appendix 1</xref>). This strategic focus enables superior identification of positive cases compared to conventional clinical diagnosis, aligning with established ML advantages in sensitivity-driven contexts [<xref rid="R8" ref-type="bibr">8</xref><xref rid="R34" ref-type="bibr">34</xref>]. This multimodal integration resonates with advancements [&#185;&#8312;F]Fluorodeoxyglucose (FDG)-positron emission tomography/CT feature integration [<xref rid="R35" ref-type="bibr">35</xref>], confirming that combining data sources overcomes single-modality constraints.</p></sec></sec><sec id="s4-3"><title>Strengths and Limitations</title><p>The core strength of our study lies in developing a comprehensive AI-driven clinical support system that uniquely bridges preoperative staging and postoperative prognosis. By integrating MRI with clinicopathological data through imbalanced-data algorithms (eg, balanced RF and weighted KNN), we significantly enhanced sensitivity for detecting parametrial invasion and lymph node metastasis preoperatively alongside postoperative recurrence and mortality. Crucially, this framework was operationalized through a clinically deployable platform enabling automated DICOM analysis, risk stratification, and individualized survival time prediction, thus forming a closed-loop decision pathway from diagnosis to follow-up.</p><p>Despite these advances, several limitations merit careful consideration. Foremost among these is the limited population and tertiary-center recruitment bias. The patient population in this study was limited and may not adequately represent the broader clinical population, particularly individuals in primary care settings or from different geographic regions. Patients were recruited from 2 specialized hospitals, which may have introduced selection bias due to potential differences in disease severity or demographic characteristics. Crucially, only 23.2% of the patients with CC initially identified possessed the necessary MRI data for modeling inclusion. This limitation stemmed primarily from the requirement for locally archived DICOM files. Importantly, most excluded patients underwent initial MRI scans at external institutions&#8212;predominantly primary care hospitals where only non-digitalized paper reports were available, precluding DICOM file retrieval. While subtle technical variations in MRI scanners or protocols across institutions may exist, their impact on model generalizability is likely minor compared to the dominant limitation of sample size scarcity. Second, the relatively short follow-up period (&lt;5 y) restricted our ability to evaluate long-term outcomes. This limitation may hinder the detection of delayed disease recurrence and treatment-related effects, especially in chronic disease contexts where complications can take several years to manifest. Third, although DL models are widely recognized for their superior performance when applied to large datasets, this study exhibited suboptimal performance due to the limited sample size and parameter constraints.</p></sec><sec id="s4-4"><title>Future Directions</title><p>To bridge these gaps and advance clinical translation, 3 strategic priorities emerge. First, we will expand the cohort through multicenter collaborations targeting 1200+ patients&#8212;deliberately enriching underrepresented positive cases&#8212;while extending follow-up beyond 5 years to capture long-term outcomes. Second, transfer learning will be implemented to develop advanced 3D CNN architectures using volumetric DICOM data, overcoming current sample size barriers and unlocking DL&#8217;s latent potential. Third, recognizing that coronal T2WI&#8212;while optimal for bilateral tumor assessment&#8212;represents only one facet of MRI&#8217;s diagnostic capability, we will implement multidimensional sequence analysis. Concurrently, we will systematically integrate axial/sagittal planes and functional sequences (DWI, DCE-MRI) to refine microinvasion detection, ultimately validating this optimized system through prospective trials assessing its impact on surgical planning and survival outcomes.</p></sec><sec id="s4-5"><title>Conclusions</title><p>In conclusion, this study used ML techniques to develop diagnostic and prognostic models using clinical and MRI data for patients with FIGO stage IA1 (LVSI+) to IIB CC. These models were designed to detect preoperative parametrial invasion and lymph node metastasis and to predict postoperative survival and recurrence. We trained and externally validated the models using data from 250 patients across 2 tertiary hospitals. In both diagnostic and prognostic applications, integrated ML models, particularly weighted KNN, demonstrated favorable performance with clinically applicable sensitivities. These findings suggest that integrated ML models may offer a valuable tool for improving preoperative staging and individualized prognosis prediction in CC, supporting more personalized and precise treatment strategies.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supplementary material</title><supplementary-material id="SAP1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.2196/69057</object-id><label>Multimedia Appendix 1</label><caption><title>Model architecture and training details, including modified 3D U-Net structure and optimized Focal Loss implementation.</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cancer-v11-e69057-s001.docx" xlink:title="DOCX File, 84 KB" id="d67e2494" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported by the Shanghai Municipal Science and Technology Commission (No. 22Y31900500; awarded to KH) and Fudan University (Medical-Engineering Interdisciplinary Project; awarded to JQ). The authors acknowledge the Institutional Ethics Committee of Fudan University Obstetrics and Gynecology Hospital for approving this retrospective multicenter cohort study (approval number: 2019&#8208;87) and the Chinese Clinical Trial Registry (ChiCTR1900028702) for its registration. An exemption was granted by the Ethics Committee for this study.</p><p>Generative AI (ChatGPT-4, OpenAI; September 2023 version) was used exclusively for minor language editing (&lt;3% of text), with all outputs verified by authors. No AI was used in research design, data handling, or clinical assessments.</p></ack><fn-group><fn fn-type="other"><p><bold>Authors&#8217; Contributions:</bold> SL and CG contributed to methodology, data acquisition, formal analysis, writing &#8211; original draft, and writing &#8211; reviewing and editing. YF, XP, and CJ contributed to methodology, data acquisition, formal analysis, and writing &#8211; reviewing and editing. HZ, LL, JX, and JW contributed to conceptualization, methodology, data acquisition, formal analysis, and writing &#8211; reviewing and editing. KH contributed to resources and supervision. JQ involved in project administration, funding acquisition, and writing &#8211; reviewing and editing.</p></fn><fn fn-type="other"><p><bold>Data Availability:</bold> Data can be made available upon reasonable request.</p></fn><fn fn-type="COI-statement"><p><bold>Conflicts of Interest:</bold> None declared.</p></fn></fn-group><notes><def-list><title>Abbreviations</title><def-item><term>AI</term><def><p>artificial intelligence</p></def></def-item><def-item><term>AUC</term><def><p>area under the receiver operating characteristic curve</p></def></def-item><def-item><term>C-index</term><def><p>concordance index</p></def></def-item><def-item><term>CC</term><def><p>cervical cancer</p></def></def-item><def-item><term>CT</term><def><p>computed tomography</p></def></def-item><def-item><term>DL</term><def><p>deep learning</p></def></def-item><def-item><term>DSI</term><def><p>depth of stromal invasion</p></def></def-item><def-item><term>DT</term><def><p>decision tree</p></def></def-item><def-item><term>FIGO</term><def><p>International Federation of Gynecology and Obstetrics</p></def></def-item><def-item><term>HPV</term><def><p>human papillomavirus</p></def></def-item><def-item><term>IQR</term><def><p>interquartile range</p></def></def-item><def-item><term>KNN</term><def><p>K-nearest neighbor</p></def></def-item><def-item><term>LVSI</term><def><p>lymph-vascular space invasion</p></def></def-item><def-item><term>MAE</term><def><p>mean absolute error</p></def></def-item><def-item><term>MCC</term><def><p>Matthews correlation coefficient</p></def></def-item><def-item><term>mIoU</term><def><p>mean intersection over union</p></def></def-item><def-item><term>ML</term><def><p>machine learning</p></def></def-item><def-item><term>MR</term><def><p>magnetic resonance</p></def></def-item><def-item><term>MRI</term><def><p>MR imaging</p></def></def-item><def-item><term>NCCN</term><def><p>National Comprehensive Cancer Network</p></def></def-item><def-item><term>OS</term><def><p>overall survival</p></def></def-item><def-item><term>PET</term><def><p>positron emission tomography</p></def></def-item><def-item><term>RF</term><def><p>random forest</p></def></def-item><def-item><term>RFS</term><def><p>recurrence-free survival</p></def></def-item><def-item><term>ROI</term><def><p>region of interest</p></def></def-item><def-item><term>T2WI</term><def><p>T2 weighted imaging</p></def></def-item></def-list></notes><ref-list><title>References</title><ref id="R1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><etal>et al</etal></person-group><article-title>Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><month>05</month><year>2021</year><volume>71</volume><issue>3</issue><fpage>209</fpage><lpage>249</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melamed</surname><given-names>A</given-names></name><name name-style="western"><surname>Margul</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Survival after minimally invasive radical hysterectomy for early-stage cervical cancer</article-title><source>N Engl J Med</source><month>Nov</month><day>15</day><year>2018</year><volume>379</volume><issue>20</issue><fpage>1905</fpage><lpage>1914</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1056/NEJMoa1804923</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">30379613</pub-id><pub-id pub-id-type="pmcid">PMC6464372</pub-id></element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abu-Rustum</surname><given-names>NR</given-names></name><name name-style="western"><surname>Yashar</surname><given-names>CM</given-names></name><name name-style="western"><surname>Arend</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>NCCN Guidelines&#174; Insights: Cervical Cancer, Version 1.2024</article-title><source>J Natl Compr Canc Netw</source><month>Dec</month><year>2023</year><volume>21</volume><issue>12</issue><fpage>1224</fpage><lpage>1233</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.6004/jnccn.2023.0062</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">38081139</pub-id></element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loubeyre</surname><given-names>P</given-names></name><name name-style="western"><surname>Navarria</surname><given-names>I</given-names></name><name name-style="western"><surname>Undurraga</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Is imaging relevant for treatment choice in early stage cervical uterine cancer?</article-title><source>Surg Oncol</source><month>Mar</month><year>2012</year><volume>21</volume><issue>1</issue><fpage>e1</fpage><lpage>6</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.suronc.2011.10.001</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">22030476</pub-id></element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polterauer</surname><given-names>S</given-names></name><name name-style="western"><surname>Grimm</surname><given-names>C</given-names></name><name name-style="western"><surname>Hofstetter</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>Nomogram prediction for overall survival of patients diagnosed with cervical cancer</article-title><source>Br J Cancer</source><month>Sep</month><day>4</day><year>2012</year><volume>107</volume><issue>6</issue><fpage>918</fpage><lpage>924</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1038/bjc.2012.340</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">22871885</pub-id><pub-id pub-id-type="pmcid">PMC3464766</pub-id></element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Establishing a nomogram for stage IA-IIB cervical cancer patients after complete resection</article-title><source>Asian Pac J Cancer Prev</source><year>2015</year><volume>16</volume><issue>9</issue><fpage>3773</fpage><lpage>3777</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.7314/apjcp.2015.16.9.3773</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">25987036</pub-id></element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>El Bouchefry</surname><given-names>K</given-names></name></person-group><part-title>Chapter 12 - learning in big data: introduction to machine learning</part-title><person-group person-group-type="editor"><name name-style="western"><surname>&#352;koda</surname><given-names>P</given-names></name><name name-style="western"><surname>Adam</surname><given-names>F</given-names></name></person-group><source>Knowledge Discovery in Big Data From Astronomy and Earth Observation</source><publisher-name>Elsevier</publisher-name><year>2020</year><fpage>225</fpage><lpage>249</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/B978-0-12-819154-5.00023-0</pub-id></element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Novel artificial intelligence machine learning approaches to precisely predict survival and site-specific recurrence in cervical cancer: a multi-institutional study</article-title><source>Transl Oncol</source><month>05</month><year>2021</year><volume>14</volume><issue>5</issue><elocation-id>101032</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.tranon.2021.101032</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">33618238</pub-id><pub-id pub-id-type="pmcid">PMC7907920</pub-id></element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charoenkwan</surname><given-names>P</given-names></name><name name-style="western"><surname>Shoombuatong</surname><given-names>W</given-names></name><name name-style="western"><surname>Nantasupha</surname><given-names>C</given-names></name><name name-style="western"><surname>Muangmool</surname><given-names>T</given-names></name><name name-style="western"><surname>Suprasert</surname><given-names>P</given-names></name><name name-style="western"><surname>Charoenkwan</surname><given-names>K</given-names></name></person-group><article-title>iPMI: machine learning-aided identification of parametrial invasion in women with early-stage cervical cancer</article-title><source>Diagnostics (Basel)</source><month>Aug</month><day>12</day><year>2021</year><volume>11</volume><issue>8</issue><elocation-id>1454</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.3390/diagnostics11081454</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">34441388</pub-id><pub-id pub-id-type="pmcid">PMC8391438</pub-id></element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Risk stratification of early-stage cervical cancer with intermediate-risk factors: model development and validation based on machine learning algorithm</article-title><source>Oncologist</source><month>Dec</month><year>2021</year><volume>26</volume><issue>12</issue><fpage>e2217</fpage><lpage>e2226</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1002/onco.13956</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">34427018</pub-id><pub-id pub-id-type="pmcid">PMC8649058</pub-id></element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>SI</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Choi</surname><given-names>CH</given-names></name><etal>et al</etal></person-group><article-title>Machine learning models to predict survival outcomes according to the surgical approach of primary radical hysterectomy in patients with early cervical cancer</article-title><source>Cancers (Basel)</source><month>07</month><day>23</day><year>2021</year><volume>13</volume><issue>15</issue><elocation-id>3709</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.3390/cancers13153709</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">34359610</pub-id><pub-id pub-id-type="pmcid">PMC8345043</pub-id></element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>P</given-names></name><name name-style="western"><surname>Sun</surname><given-names>G</given-names></name><name name-style="western"><surname>Wei</surname><given-names>S</given-names></name></person-group><article-title>Application of deep learning algorithm in cervical cancer MRI image segmentation based on wireless sensor</article-title><source>J Med Syst</source><month>Apr</month><day>26</day><year>2019</year><volume>43</volume><issue>6</issue><elocation-id>156</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.1007/s10916-019-1284-7</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">31028491</pub-id></element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name><name name-style="western"><surname>Bell</surname><given-names>D</given-names></name><name name-style="western"><surname>Antani</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>An observational study of deep learning and automated evaluation of cervical images for cancer screening</article-title><source>J Natl Cancer Inst</source><month>Sep</month><day>1</day><year>2019</year><volume>111</volume><issue>9</issue><fpage>923</fpage><lpage>932</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1093/jnci/djy225</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">30629194</pub-id><pub-id pub-id-type="pmcid">PMC6748814</pub-id></element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>YR</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Ju</surname><given-names>W</given-names></name><name name-style="western"><surname>Nam</surname><given-names>K</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KG</given-names></name></person-group><article-title>Comparison of machine and deep learning for the classification of cervical cancer based on cervicography images</article-title><source>Sci Rep</source><month>Aug</month><day>9</day><year>2021</year><volume>11</volume><issue>1</issue><fpage>16143</fpage><comment>doi</comment><pub-id pub-id-type="doi">10.1038/s41598-021-95748-3</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">34373589</pub-id><pub-id pub-id-type="pmcid">PMC8352876</pub-id></element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Development of a deep learning model to identify lymph node metastasis on magnetic resonance imaging in patients with cervical cancer</article-title><source>JAMA Netw Open</source><month>07</month><day>1</day><year>2020</year><volume>3</volume><issue>7</issue><elocation-id>e2011625</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.11625</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">32706384</pub-id><pub-id pub-id-type="pmcid">PMC7382006</pub-id></element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>T</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Cui</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Development and validation of a deep learning radiomics model predicting lymph node status in operable cervical cancer</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><elocation-id>464</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.3389/fonc.2020.00464</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">32373511</pub-id><pub-id pub-id-type="pmcid">PMC7179686</pub-id></element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Guan</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Development and validation of a deep learning algorithm for auto-delineation of clinical target volume and organs at risk in cervical cancer radiotherapy</article-title><source>Radiother Oncol</source><month>Dec</month><year>2020</year><volume>153</volume><fpage>172</fpage><lpage>179</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.radonc.2020.09.060</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">33039424</pub-id></element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jajodia</surname><given-names>A</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Prosch</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Combination of radiomics and machine learning with diffusion-weighted MR imaging for clinical outcome prognostication in cervical cancer</article-title><source>Tomography</source><month>Aug</month><day>5</day><year>2021</year><volume>7</volume><issue>3</issue><fpage>344</fpage><lpage>357</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.3390/tomography7030031</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">34449713</pub-id><pub-id pub-id-type="pmcid">PMC8396356</pub-id></element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koh</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Greer</surname><given-names>BE</given-names></name><name name-style="western"><surname>Abu-Rustum</surname><given-names>NR</given-names></name><etal>et al</etal></person-group><article-title>Cervical Cancer</article-title><source>J Natl Compr Canc Netw</source><month>Mar</month><year>2013</year><volume>11</volume><issue>3</issue><fpage>320</fpage><lpage>343</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.6004/jnccn.2013.0043</pub-id><pub-id pub-id-type="pmid">23486458</pub-id></element-citation></ref><ref id="R20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koh</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Greer</surname><given-names>BE</given-names></name><name name-style="western"><surname>Abu-Rustum</surname><given-names>NR</given-names></name><etal>et al</etal></person-group><article-title>Cervical Cancer, Version 2.2015</article-title><source>J Natl Compr Canc Netw</source><month>Apr</month><year>2015</year><volume>13</volume><issue>4</issue><fpage>395</fpage><lpage>404</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.6004/jnccn.2015.0055</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">25870376</pub-id></element-citation></ref><ref id="R21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koh</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Abu-Rustum</surname><given-names>NR</given-names></name><name name-style="western"><surname>Bean</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology</article-title><source>J Natl Compr Canc Netw</source><month>01</month><year>2019</year><volume>17</volume><issue>1</issue><fpage>64</fpage><lpage>84</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.6004/jnccn.2019.0001</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">30659131</pub-id></element-citation></ref><ref id="R22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sedlis</surname><given-names>A</given-names></name><name name-style="western"><surname>Bundy</surname><given-names>BN</given-names></name><name name-style="western"><surname>Rotman</surname><given-names>MZ</given-names></name><name name-style="western"><surname>Lentz</surname><given-names>SS</given-names></name><name name-style="western"><surname>Muderspach</surname><given-names>LI</given-names></name><name name-style="western"><surname>Zaino</surname><given-names>RJ</given-names></name></person-group><article-title>A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study</article-title><source>Gynecol Oncol</source><month>05</month><year>1999</year><volume>73</volume><issue>2</issue><fpage>177</fpage><lpage>183</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1006/gyno.1999.5387</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">10329031</pub-id></element-citation></ref><ref id="R23"><label>23.</label><element-citation publication-type="book"><person-group person-group-type="editor"><name name-style="western"><surname>Ronneberger</surname><given-names>O</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>P</given-names></name><name name-style="western"><surname>Brox</surname><given-names>T</given-names></name></person-group><source>U-Net: Convolutional Networks for Biomedical Image Segmentation</source><publisher-name>Springer</publisher-name><year>2015</year><comment>URL</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://link.springer.com/chapter/10.1007/978-3-319-24574-4_28" ext-link-type="uri">https://link.springer.com/chapter/10.1007/978-3-319-24574-4_28</ext-link><comment>Accessed</comment><date-in-citation>02-09-2025</date-in-citation></element-citation></ref><ref id="R24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L</given-names></name><name name-style="western"><surname>Albanie</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>G</given-names></name><name name-style="western"><surname>Wu</surname><given-names>E</given-names></name></person-group><article-title>Squeeze-and-Excitation networks</article-title><source>IEEE Trans Pattern Anal Mach Intell</source><month>Aug</month><year>2020</year><volume>42</volume><issue>8</issue><fpage>2011</fpage><lpage>2023</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1109/TPAMI.2019.2913372</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">31034408</pub-id></element-citation></ref><ref id="R25"><label>25.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Goodfellow</surname><given-names>I</given-names></name><name name-style="western"><surname>Bengio</surname><given-names>Y</given-names></name><name name-style="western"><surname>Courville</surname><given-names>A</given-names></name></person-group><source>Deep Learning</source><publisher-name>MIT Press</publisher-name><year>2016</year><comment>URL</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.deeplearningbook.org/" ext-link-type="uri">https://www.deeplearningbook.org/</ext-link><comment>Accessed</comment><date-in-citation>02-09-2025</date-in-citation><comment>ISBN</comment><pub-id pub-id-type="isbn">0262337371</pub-id></element-citation></ref><ref id="R26"><label>26.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>TY</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>P</given-names></name><name name-style="western"><surname>Girshick</surname><given-names>R</given-names></name><name name-style="western"><surname>He</surname><given-names>K</given-names></name><name name-style="western"><surname>Dollar</surname><given-names>P</given-names></name></person-group><article-title>Focal loss for dense object detection</article-title><comment>Presented at</comment><conf-name>2017 IEEE International Conference on Computer Vision (ICCV)</conf-name><conf-date>Oct 22-29, 2017</conf-date><conf-loc>Venice</conf-loc><year>2017</year><comment>doi</comment><pub-id pub-id-type="doi">10.1109/ICCV.2017.324</pub-id></element-citation></ref><ref id="R27"><label>27.</label><element-citation publication-type="webpage"><source>Website: AI-Assisted Contouring and Prognosis Prediction System</source><comment>URL</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://aigja.fckyy.org.cn/zcpt/login" ext-link-type="uri">https://aigja.fckyy.org.cn/zcpt/login</ext-link><comment>Accessed</comment><date-in-citation>02-09-2025</date-in-citation></element-citation></ref><ref id="R28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>JR</given-names></name><name name-style="western"><surname>Qin</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal>et al</etal></person-group><article-title>Predicting parametrial invasion in cervical carcinoma (stages IB1, IB2, and IIA): diagnostic accuracy of T2-weighted imaging combined with DWI at 3T</article-title><source>AJR AM J Roentgenol</source><month>Mar</month><year>2018</year><volume>210</volume><issue>3</issue><fpage>677</fpage><lpage>684</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.2214/AJR.17.18104</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">29323549</pub-id></element-citation></ref><ref id="R29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumoto</surname><given-names>YK</given-names></name><name name-style="western"><surname>Kido</surname><given-names>A</given-names></name><name name-style="western"><surname>Moribata</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Diagnostic accuracy of magnetic resonance imaging for International Federation of Gynecology and Obstetrics 2018 IB to IIB cervical cancer staging: comparison among magnetic resonance sequences and pathologies</article-title><source>J Comput Assist Tomogr</source><year>2021</year><volume>45</volume><issue>6</issue><fpage>829</fpage><lpage>836</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1097/RCT.0000000000001210</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">34407060</pub-id></element-citation></ref><ref id="R30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>CQ</given-names></name><name name-style="western"><surname>Li</surname><given-names>XJ</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>ZY</given-names></name><name name-style="western"><surname>Xin</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name></person-group><article-title>Imaging based artificial intelligence for predicting lymph node metastasis in cervical cancer patients: a systematic review and meta-analysis</article-title><source>Front Oncol</source><year>2025</year><volume>15</volume><elocation-id>1532698</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.3389/fonc.2025.1532698</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">40094016</pub-id><pub-id pub-id-type="pmcid">PMC11906327</pub-id></element-citation></ref><ref id="R31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Gao</surname><given-names>T</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Preoperative prediction of parametrial invasion in early-stage cervical cancer with MRI-based radiomics nomogram</article-title><source>Eur Radiol</source><month>Jun</month><year>2020</year><volume>30</volume><issue>6</issue><fpage>3585</fpage><lpage>3593</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1007/s00330-019-06655-1</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">32065284</pub-id></element-citation></ref><ref id="R32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uddin</surname><given-names>S</given-names></name><name name-style="western"><surname>Haque</surname><given-names>I</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name><name name-style="western"><surname>Moni</surname><given-names>MA</given-names></name><name name-style="western"><surname>Gide</surname><given-names>E</given-names></name></person-group><article-title>Comparative performance analysis of K-nearest neighbour (KNN) algorithm and its different variants for disease prediction</article-title><source>Sci Rep</source><month>Apr</month><day>15</day><year>2022</year><volume>12</volume><issue>1</issue><elocation-id>6256</elocation-id><comment>doi</comment><pub-id pub-id-type="doi">10.1038/s41598-022-10358-x</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">35428863</pub-id><pub-id pub-id-type="pmcid">PMC9012855</pub-id></element-citation></ref><ref id="R33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dou</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Merkurjev</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Machine learning methods for small data challenges in molecular science</article-title><source>Chem Rev</source><month>07</month><day>12</day><year>2023</year><volume>123</volume><issue>13</issue><fpage>8736</fpage><lpage>8780</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1021/acs.chemrev.3c00189</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">37384816</pub-id><pub-id pub-id-type="pmcid">PMC10999174</pub-id></element-citation></ref><ref id="R34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuo</surname><given-names>K</given-names></name><name name-style="western"><surname>Purushotham</surname><given-names>S</given-names></name><name name-style="western"><surname>Moeini</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>A pilot study in using deep learning to predict limited life expectancy in women with recurrent cervical cancer</article-title><source>Am J Obstet Gynecol</source><month>Dec</month><year>2017</year><volume>217</volume><issue>6</issue><fpage>703</fpage><lpage>705</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1016/j.ajog.2017.08.012</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">28843741</pub-id><pub-id pub-id-type="pmcid">PMC7534808</pub-id></element-citation></ref><ref id="R35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>WC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>SW</given-names></name><name name-style="western"><surname>Wu</surname><given-names>KC</given-names></name><etal>et al</etal></person-group><article-title>Prediction of local relapse and distant metastasis in patients with definitive chemoradiotherapy-treated cervical cancer by deep learning from [<sup>18</sup>F]-fluorodeoxyglucose positron emission tomography/computed tomography</article-title><source>Eur Radiol</source><month>Dec</month><year>2019</year><volume>29</volume><issue>12</issue><fpage>6741</fpage><lpage>6749</lpage><comment>doi</comment><pub-id pub-id-type="doi">10.1007/s00330-019-06265-x</pub-id><comment>Medline</comment><pub-id pub-id-type="pmid">31134366</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>